Long-term silencing of autoimmune diabetes and improved life expectancy by a soluble pHLA-DR4 chimera in a newly-humanized

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 3, 2014, Pages 693-699

  Sang, Luis Pow ^a   Majji, Sai ^b   Casares, Sofia ^a,b   Brumeanu, Teodor D ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

HLA humanized nod mouse; HLA peptide chimera; T1d prevention and stabilization

Indexed keywords

B7 ANTIGEN; CHIMERIC PROTEIN; GLUTAMATE DECARBOXYLASE 65; HLA DR4 ANTIGEN; HLA DR4 GLUTAMATE DECARBOXYLASE 65 CHIMERA; UNCLASSIFIED DRUG; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2; HLA ANTIGEN CLASS 2; TNFRSF10A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; CHEMOPROPHYLAXIS; CHIMERA; CONTROLLED STUDY; DRUG EFFECT; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LIFE EXPECTANCY; MOUSE; NONHUMAN; PANCREAS; SINGLE DRUG DOSE; T LYMPHOCYTE; TH2 CELL; ANIMAL; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; LONGEVITY; METABOLISM; PATHOLOGY; SCID MOUSE; SURVIVAL; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; GLUTAMATE DECARBOXYLASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LONGEVITY; MICE; MICE, SCID; MICE, TRANSGENIC; PANCREAS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84898410158     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27374     Document Type: Article

References (23)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358:221-9; PMID:11476858; http://dx.doi.org/10.1016/S0140-6736(01)05415-0
2. Driver JP, Serreze DV, Chen YG. Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol 2011; 33:67-87; PMID:20424843; http://dx.doi.org/10.1007/s00281- 010-0204-1
3. Chao CC, Sytwu HK, Chen EL, Toma J, McDevitt HO. The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire. Proc Natl Acad Sci U S A 1999; 96:9299-304; PMID:10430937; http://dx.doi.org/10.1073/pnas.96.16.9299
4. Preda I, McEvoy RC, Lin M, Bona CA, Rapaport R, Brumeanu TD, Casares S. Soluble, dimeric HLA DR4-peptide chimeras: an approach for detection and immunoregulation of human type-1 diabetes. Eur J Immunol 2005; 35:2762-75; PMID:16106371; http://dx.doi.org/10.1002/eji.200526158
5. Skyler JS. Immunomodulation for type 1 diabetes mellitus. Int J Clin Pract Suppl 2010; 166:59-63; PMID:20377666; http://dx.doi.org/10.1111/j.1742- 1241.2009.02280.x
6. Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, Quattrin T. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009; 32:1244-9; PMID:19366957; http://dx.doi.org/10.2337/dc09-0054
7. Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simões BP, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009; 301:1573-9; PMID:19366777; http://dx.doi.org/10.1001/jama. 2009.470
8. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008; 105:18895-900; PMID:19015530; http://dx.doi.org/10.1073/pnas.0810246105
9. Marzorati S, Bocca N, Molano RD, Hogan AR, Doni M, Cobianchi L, Inverardi L, Ricordi C, Pileggi A. Effects of systemic immunosuppression on islet engraftment and function into a subcutaneous biocompatible device. Transplant Proc 2009; 41:352-3; PMID:19249555; http://dx.doi.org/10.1016/j.transproceed. 2008.09.057
10. Pedotti R, Sanna M, Tsai M, DeVoss J, Steinman L, McDevitt H, Galli SJ. Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus. BMC Immunol 2003; 4:2; PMID:12597780; http://dx.doi.org/10.1186/1471-2172-4-2
11. Li L, Yi Z, Wang B, Tisch R. Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination. J Immunol 2009; 183:4809-16; PMID:19752238; http://dx.doi.org/10.4049/jimmunol.0901616
12. Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone JA. Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol 2003; 171:5587-95; PMID:14607967
13. Casares S, Hurtado A, McEvoy RC, Sarukhan A, von Boehmer H, Brumeanu TD. Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera. Nat Immunol 2002; 3:383-91; PMID:11862219; http://dx.doi.org/10.1038/ni770
14. Lin M, Stoica-Nazarov C, Surls J, Kehl M, Bona C, Olsen C, Brumeanu TD, Casares S. Reversal of type 1 diabetes by a new MHC II-peptide chimera: "Single-epitope-mediated suppression" to stabilize a polyclonal autoimmune T-cell process. Eur J Immunol 2010; 40:2277-88; PMID:20540111; http://dx.doi.org/10.1002/eji.200940094
15. Casares S, Lin M, Zhang N, Teijaro JR, Stoica C, McEvoy R, Farber DL, Bona C, Brumeanu TD. A peptide-major histocompatibility complex II chimera favors survival of pancreatic beta-islets grafted in type 1 diabetic mice. Transplantation 2008; 85:1717-25; PMID:18580462; http://dx.doi.org/10.1097/TP. 0b013e31817752cc
16. Preda-Pais A, Stan AC, Casares S, Bona C, Brumeanu T-D. Efficacy of clonal deletion vs. anergy of self-reactive CD4 T-cells for the prevention and reversal of autoimmune diabetes. J Autoimmun 2005; 25:21-32; PMID:16005609; http://dx.doi.org/10.1016/j.jaut.2005.04.003
17. Casares S, Zong CS, Radu DL, Miller A, Bona CA, Brumeanu TD. Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation. J Exp Med 1999; 190:543-53; PMID:10449525; http://dx.doi.org/ 10.1084/jem.190.4.543
18. Wong S, Guerder S, Visintin I, Reich E-P, Swenson KE, Flavell RA, Janeway CA Jr. Expression of the co-stimulator molecule B7-1 in pancreatic β-cells accelerates diabetes in the NOD mouse. Diabetes 1995; 44:326-9; PMID:7533734; http://dx.doi.org/10.2337/diab.44.3.326
19. Rajagopalan G, Kudva YC, Chen L, Wen L, David CS. Autoimmune diabetes in HLA-DR3/DQ8 transgenic mice expressing the co-stimulatory molecule B7-1 in the beta cells of islets of Langerhans. Int Immunol 2003; 15:1035-44; PMID:12917255; http://dx.doi.org/10.1093/intimm/dxg103
20. Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert JJ, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012; 366:433-42; PMID:22296077; http://dx.doi.org/10.1056/NEJMoa1107096
21. Casares S, Brumeanu TD. Insights into the pathogenesis of type 1 diabetes: a hint for novel immunospecific therapies. Curr Mol Med 2001; 1:357-78; PMID:11899083; http://dx.doi.org/10.2174/1566524013363753
22. Casares S, Bona CA, Brumeanu TD. Engineering and characterization of a murine MHC class II-immunoglobulin chimera expressing an immunodominant CD4 T viral epitope. Protein Eng 1997; 10:1295-301; PMID:9514118; http://dx.doi.org/ 10.1093/protein/10.11.1295
23. Ito K, Bian HJ, Molina M, Han J, Magram J, Saar E, Belunis C, Bolin DR, Arceo R, Campbell R, et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 1996; 183:2635-44; PMID:8676084; http://dx.doi.org/10.1084/jem.183.6.2635